The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof ##STR00001##
in which q, R.sup.11, R.sup.12, R.sup.13 and R.sup.14 are as defined in the specification, for use in therapy.

The disclosure teaches the use of antistatic materials in the airway for thermal aerosol generation devices. The present disclosure teaches the use of antistatic materials for drug delivery in any drug that may be susceptible to charging during aerosol generation.

An object of the present invention is to provide a compound having an anti-inflammatory activity or a pharmacologically acceptable salt thereof. The solution of the present invention is a compound of general formula (1) or a pharmacologically acceptable salt thereof. ##STR00001##
wherein the symbols in the formula are defined below:
A: e.g., Benzene, E: e.g., —CH.sub.2—, G: e.g., a 5-membered aromatic heterocyclic ring, X: e.g., cyclohexane, J: e.g., a 5-membered aromatic heterocyclic ring, Y: e.g., a phenyl group, R.sup.1, R.sup.2, R.sup.3: e.g., a halogen atom, R.sup.4: e.g., a C1-C6 alkyl group, R.sup.5: e.g., a hydrogen atom, R.sup.6a, R.sup.6b, R.sup.6c, R.sup.6d: e.g., a hydrogen atom, R.sup.7: e.g., a hydrogen atom, R.sup.8: e.g., a hydrogen atom, n.sup.1, n.sup.2, n.sup.3: e.g., 1.

Provided herein in some embodiments are methods of treating a sleep disorder associated with pain in a patient in need thereof, comprising administering to the patient a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Provided herein in some embodiments are methods of treating a sleep disorder associated with pain in a patient in need thereof, comprising: a) identifying a patient having a sleep disorder associated with pain; and b) administering to the patient identified in step a) a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Provided herein in some embodiments are methods of treating a sleep disorder associated with pain in a patient in need thereof, comprising: a) selecting a patient having a sleep disorder associated with pain; and b) administering to the patient identified in step a) a compound of Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, the sleep disorder is selected from the group consisting of difficulty with falling asleep; restlessness of sleep; difficulty getting comfortable; difficulty staying asleep; degree of deep sleep; degree of being rested when waking up for the day; difficulty with beginning the day; and degree of having enough sleep during the previous night. In some embodiments, the sleep disorder is associated with pain selected from the group consisting of fibromyalgia, neuropathic pain, osteoarthritis, and visceral pain. In some more particular embodiments, the visceral pain is selected from the group consisting of IBS associated pain and bladder pain.

Provided herein in some embodiments are methods of treating a sleep disorder associated with pain in a patient in need thereof, comprising administering to the patient a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Provided herein in some embodiments are methods of treating a sleep disorder associated with pain in a patient in need thereof, comprising: a) identifying a patient having a sleep disorder associated with pain; and b) administering to the patient identified in step a) a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Provided herein in some embodiments are methods of treating a sleep disorder associated with pain in a patient in need thereof, comprising: a) selecting a patient having a sleep disorder associated with pain; and b) administering to the patient identified in step a) a compound of Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, the sleep disorder is selected from the group consisting of difficulty with falling asleep; restlessness of sleep; difficulty getting comfortable; difficulty staying asleep; degree of deep sleep; degree of being rested when waking up for the day; difficulty with beginning the day; and degree of having enough sleep during the previous night. In some embodiments, the sleep disorder is associated with pain selected from the group consisting of fibromyalgia, neuropathic pain, osteoarthritis, and visceral pain. In some more particular embodiments, the visceral pain is selected from the group consisting of IBS associated pain and bladder pain.

Embodiments relate to a method for treatment of a sleep disorder and to compositions comprising tetrahydrocannabinol (THC), cannabidiol (CBD), and cannabinol (CBN), wherein the ratio of THC:CBD:CBN by weight is A:B:C where A is between 0.0001 and 1, B is 1, and C is between 0.05 and 1. Optionally A is between 0.001 and 0.02, B is 1 and C is between 0.2 and 0.7.

Embodiments relate to a method for treatment of a sleep disorder and to compositions comprising tetrahydrocannabinol (THC), cannabidiol (CBD), and cannabinol (CBN), wherein the ratio of THC:CBD:CBN by weight is A:B:C where A is between 0.0001 and 1, B is 1, and C is between 0.05 and 1. Optionally A is between 0.001 and 0.02, B is 1 and C is between 0.2 and 0.7.

A probiotic composition for treating rapid eye movement sleep behavior disorder, is prepared from Bacillus licheniformis, Bifidobacterium longum, Lactobacillus acidophilus, Enterococcus faecalis, and pharmaceutically acceptable adjuvants. The probiotic composition can improve the symptoms of rapid eye movement sleep behavior disorder of a patient, improve RBD symptoms of idiopathic RBD patients and PD patients, improve the motor symptoms and reduce the daily levodopa equivalent dose in PD patients.

An earplug (1) for administering a fluid agent into an ear canal is provided. The earplug (1) comprises a first part (10) adapted for insertion in the ear canal. The first part comprises an elongated member (11) having a chamber (12) for containing the fluid agent, the chamber (12) having at least one outlet (13) at a proximal end (14) of the elongated member (11); and a malleable member (17) disposed laterally of the elongated member (11). The earplug (1) further comprises a second part (20) comprising a piston (21). The piston (21) has a first end (22) which is insertable in the elongated member (11), and a second end (23) which has a push member (24). The piston (21) is displaceable from a first position (A) distally of the chamber (12) to a second position (B) within the chamber (12), such that the fluid agent is injected from the chamber (12) through the outlet (13) into the ear canal.

The disclosure provides compounds of formula (I): ##STR00001##
said compounds being inhibitors of Kv3 channels and of use in the prophylaxis or treatment of related disorders.